Primary myelofibrosis (PMF) is a Myeloproliferative Neoplasm (MPN) characterized by megakaryocyte hyperplasia, progressive bone marrow fibrosis, extramedullary hematopoiesis and transformation to Acute Myeloid Leukemia (AML). A number of phenotypic driver (JAK2, CALR, MPL) and additional subclonal mutations have been described in PMF, pointing to a complex genomic landscape. To discover novel genomic lesions that can contribute to disease phenotype and/or development, gene expression and copy number signals were integrated and several genomic abnormalities leading to a concordant alteration in gene expression levels were identified. In particular, copy number gain in the polyamine oxidase (PAOX) gene locus was accompanied by a coordinated transcriptional up-regulation in PMF patients. PAOX inhibition resulted in rapid cell death of PMF progenitor cells, while sparing normal cells, suggesting that PAOX inhibition could represent a therapeutic strategy to selectively target PMF cells without affecting normal hematopoietic cells' survival. Moreover, copy number loss in the chromatin modifier HMGXB4 gene correlates with a concomitant transcriptional down-regulation in PMF patients. Interestingly, silencing of HMGXB4 induces megakaryocyte differentiation, while inhibiting erythroid development, in human hematopoietic stem/progenitor cells. These results highlight a previously un-reported, yet potentially interesting role of HMGXB4 in the hematopoietic system and suggest that genomic and transcriptional imbalances of HMGXB4 could contribute to the aberrant expansion of the megakaryocytic lineage that characterizes PMF patients.
TET2, EZH2, IDH1 and IDH2, 3 as well as in genes involved in mRNA splicing, such as SF3B1 and U2AF2, 4 have also been reported in recent years in patients with BCR-ABL1negative MPNs. In 2013, two independent groups reported the discovery of mutations in the calreticulin gene (CALR) in 60-80% of JAK2 and MPL unmutated ET and PMF patients. 5, 6 Mutations leading to dysregulation of JAK-STAT pathway are a common feature of MPNs, however, whether predating genetic abnormality/ies that are responsible for the onset of the MPN disease do occur, is still largely debated.
In the last few years, Single Nucleotide Polymorphisms (SNPs) arrays have been proven to be a sensitive technology capable of achieving high resolution genome-wide DNA copy number analysis and detection of segmental region of homozygosity (Copy Number Neutral Loss of Heterozygosity [CNN-LOH]). In particular, SNP arrays have been shown to increase the detection rate of chromosomal abnormalities compared with karyotyping and to identify clinically significant copy number aberrations in genomic regions that have not been targeted by routine karyotyping or FISH probes. [7] [8] [9] In this study, we performed SNP and gene expression profiling on a set of 31 PMF samples. Taking advantage of the high sensitivity of Cytoscan HD arrays, we detected several novel recurrent chromosomal abnormalities in our sample set. To select those chromosomal aberrations that have higher chances to effectively impact on disease development and/or phenotype, we integrated copy number (CN) data with gene expression (GE) profiles. 10, 11 This integrative approach allows detecting genomic regions with coordinated CN alterations and changes in transcriptional levels, thereby identifying genomic aberrations that have a direct impact on gene expression level and, therefore, are more likely to play a functional role. 12 By integrative analysis, we discovered that PMF samples are characterized by genomic and transcriptional alterations in the polyamine oxidase PAOX and in the chromatin modifier HMGXB4. Both loci resulted of particular interest since the inhibition of PAOX induced a rapid cell death in PMF progenitor cells, while silencing of HMGXB4 produced the expansion of the megakaryocytic lineage, a feature commonly observed in PMF patients.
Material and Methods

Patients and samples
Thirty-one patients with a diagnosis of PMF in a typical fibrotic stage of the disease according to the World Health Organization (WHO) 13 were included in the study. Their characteristics are reported in Table S1 , Supporting Information. PMF CD341 cells were purified from peripheral blood (PB). In addition, 16 PB samples and 15 bone marrow (BM) samples were collected from normal donors.
Ethics committee approval. All subjects provided informed written consent, and the study was performed under the local Institutional Review Board's approved protocol (Florence: approval date: April 22, 2011, approval file number # 2011/ 0014777; Pavia: approval date: February 24, 2011, file number #174). The study was conducted in accordance with the Declaration of Helsinki.
Cell isolation CD341 cells were purified from 30 to 50 mL of PB collected from PMF patients, from 150 mL of PB from G-CSF untreated healthy donors, or from 5 mL of BM aspirates, all obtained in preservative-free heparin. Mononuclear cells were separated over a Ficoll-Paque gradient (Lympholyte; Cederlane Labs) and processed through two sequential steps of immunomagnetic CD341 selection (Miltenyi Biotec; Bergisch Gladbach, Germany). Purity of the isolated CD341 cell population was evaluated by flow cytometry after labeling with PE-HPCA2 anti-CD34 monoclonal antibody (BD Biosciences) and was always greater than 95%. CD341 cells (3 3 10 5 ) were immediately lysed in Qiazol (Qiagen; Valencia, CA). Granulocytes were isolated from the pellet of the Ficoll-Paque gradient after Ammonium Chloride lysis of red blood cells, by means of immunomagnetic CD161 selection (Miltenyi Biotec; Bergisch Gladbach, Germany). 14 Umbilical cord blood (CB) samples from normal donors were collected after normal deliveries, according to the institutional guidelines for discarded material. CD341 CB cells were purified as previously described. 15 RNA extraction and gene expression profiling (GEP). GEP was performed on RNA isolated from CD341 cells of 31 PMF patients and 31 healthy donors (n 5 15 BM, n 5 16 PB) as described in Norfo et al. 16 Samples were hybridized on Affymetrix HG-U219 microarrays. Microarray data were submitted to the Gene Expression Omnibus repository (GEO; http://www.ncbi.nlm.nih.gov/geo) and can be downloaded as GSE41812 and GSE53482 series.
SNP array analysis. DNA was extracted from granulocytes obtained from the same 31 PMF patients analyzed for GEP. Briefly, DNA was extracted by means of DNeasy Blood & What's new? Primary myelofibrosis (PMF) is a proliferative hematopoietic stem cell disorder associated in some cases with mutations in the JAK-STAT signal transduction pathway. Here the authors performed a detailed genetic analysis of blood and bone marrow samples and identified the gain of function of the polyamine oxidase PAOX and the loss of function of the chromatin modifier HMGXB4 as novel genomic abnormalities in PMF. This brings new insight into the mechanism of PMF development as in vitro manipulations of the two factors affected resistance to apoptosis and hyperplastic megakaryopoiesis, both features of PMF.
Tissue Kit (Qiagen) following the manufacturer's recommendations. NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies; Wilmington, DE) was used to evaluate the DNA sample concentration, while 260/280 nm and 260/ 230 nm ratios were used to assess DNA purity. DNA (250 ng) was then digested, amplified, purified, fragmented and labeled following Affymetrix's protocols. Labeled DNA was hybridized on Affymetrix Cytoscan HD Arrays. Scanning was performed using the GeneChip system 3000 7G according to the manufacturer's instructions (Affymetrix). Data were submitted to the Gene Expression Omnibus repository (GEO; http://www.ncbi.nlm.nih.gov/geo) and can be downloaded as GSE 69161 series.
Integrated analysis of GEP and copy number variation (CNV) data
The integrative analysis of gene expression and copy number data was performed using PREDA (Position RElated Data Analysis), an R Bioconductor package to detect regional variations in genomic features from high-throughput data. 11 PREDA is particularly suited for the identification of chromosomal regions with coordinated copy number and transcriptional imbalances. 10 The computational framework integrates copy number and gene expression profiles at genome-wide level, by statistically assessing the gene dosage and transcription status on common genomic positions. Specifically, CN data are transformed into a score, which quantifies, for each SNP in any sample, the amplitude of the CN variation from the diploid status estimated using HapMap (http://hapmap. ncbi.nlm.nih.gov/index.html.en) data as a reference. Similarly, a GE score is defined as the differential expression in two populations of any microarray probe set. CN and GE scores are then estimated at the same gene positions using a kernel regression estimator with an automatically adapted local plug-in bandwidth. Finally, a permutation scheme is used to identify genes with statistically significant CN/GE imbalances under the assumption that each chromosomal position has a unique CN/GE characteristic and that the corresponding score is not comparable with any score in other positions of the genome. The copy number (or gene expression) status of a gene is defined as loss (down-regulation) or gain (up-regulation) when the false discovery rate (expressed by the q-value) is below a given threshold and the CN score (GE score) is smaller than a low score threshold or larger than a high score threshold, respectively.
For CN calculation, Signal Log to Ratio were quantified by ChAS software using HapMap data (http://hapmap.ncbi. nlm.nih.gov/index.html.en) as a reference, while gene expression levels were estimated using RMA algorithm directly from raw microarray data. Both data were used as input to PREDA to identify regions concomitantly harboring CN loss and down-regulated genes or CN gain and up-regulated genes (deleted and amplified regions, respectively). To further validate the presence of areas of deletion and amplification, we intersected the list of deleted and amplified genes with the list of differentially expressed genes obtained comparing the expression levels of 31 PMF patients with 31 healthy donors using SAM 17 (Significant Analysis of Microarray) algorithm.
Quantitative reverse transcription polymerase chain reaction (qRT-PCR)
Total RNA (100 ng) was reverse-transcribed to cDNA using a High Capacity cDNA Archive Kit (Life technologies; Carlsbad, CA). TaqMan PCR was carried out using the 23 Taq-Man OpenArrayReal-Time PCR master mix and TaqMan gene expression assays (all reagents from Life Technologies), by means of the QuantStudio 12K Flex Real-Time PCR System (Life Technologies). Assays were performed in triplicate. Gene expression profiling was achieved using the comparative cycle threshold (CT) method of relative quantitation using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the housekeeping gene. Data analysis was performed by means of Expression Suite Software (Life Technologies). To normalize data, DDCTs were calculated for each sample using the median DCTs measured among the entire population of subjects (PMF patients and healthy donors) for calibration. Thus, the relative quantity (RQ) value (52^-DDCT) represents the mRNA expression for each sample relative to the median expression of that mRNA in all subjects.
Electroporation of CD341 cells
Human CD341 cells were transfected by using the 4D-Nucleofector TM System (Lonza) as previously reported. 18 Briefly, each sample was electroporated three times once every 24 hrs (h) with a mix of three Silencer Select small interfering RNAs (siRNAs) targeting the mRNAs of interest (Table S3 , Supporting Information) (Life Technologies), starting from the day after CD341 cell purification. For each electroporation, 4 3 10 5 CD341 cells were resuspended in 100 mL of P3 Primary Cell Solution (Lonza), containing 3 mg of siRNA mix, and pulsed with the program DS112. To exclude non-specific effects caused by interfering RNA (RNAi) nucleofection, a sample transfected with a nontargeting siRNA (NegCTR; Silencer Select Negative Control #2 siRNA; Life Technologies) was included. Cells were analyzed 24 h and 48 h after the last nucleofection for both cell viability and target mRNAs' expression.
CD341 cell-culture conditions
After immunomagnetic separation, CD341 cells were seeded in 24-well plates at 5 3 10 5 /mL in serum-free medium SYN-H (ABCell-Bio, Paris, France), supplemented with stem cell factor (SCF; 50 ng/mL), Fms-like tyrosine kinase 3 ligand (Flt3L; 50 ng/mL), thrombopoietin (THPO; 20 ng/mL), interleukin-6 (IL-6; 10 ng/mL) and interleukin-3 (IL-3; 10 ng/mL; all from Miltenyi). After each transfection, cells were transferred into pre-warmed fresh medium in 24-well plates and maintained in the same culture conditions as described above.
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For liquid culture differentiation assays, 24 h after the last nucleofection (hereafter reported as post-nucleofection) CD341 cells were plated (5 3 10 5 /mL) in: (a) multi-lineage differentiation medium: IMDM added with 20% BIT serum substitute (bovine serum albumin, insulin and transferrin; StemCell Technologies), supplemented with SCF (50 ng/mL), Flt3L (50 ng/mL), THPO (20 ng/mL), IL-6 (10 ng/mL) and IL-3 (10 ng/mL); 16 (b) Mk-differentiation medium: serumfree medium SYN-H (ABCell-Bio, Paris, France) supplemented with SCF (5 ng/mL), THPO (50 ng/mL), IL11 (40 ng/mL), IL3 (2 ng/mL) and IL6 (1 ng/mL); 19 (c) erythroid differentiation medium: IMDM added with 20% BIT serum substitute (StemCell Technologies) supplemented with erythropoietin (EPO; 0.4 U/mL; R&D Systems) and SCF (50 ng/ mL; Miltenyi); 18 (all cytokines from Miltenyi Biotec). The medium was replaced every 3 days.
PAOX inhibition in MNCs and CD341 cells
MNCs and CD341 cells were obtained from PMF patients and CB samples as described above. CD341 cells were seeded at 5 3 10 5 /mL in IMDM supplemented with 20% BIT serum substitute (bovine serum albumin, insulin and transferrin; StemCell Technologies), SCF (50 ng/mL), Flt3L (50 ng/mL), THPO (20 ng/mL), IL-6 (10 ng/mL) and IL-3 (10 ng/mL). MNCs were seeded at 1 3 10 6 /mL in IMDM supplemented with 20% FBS (Sigma-Aldrich). Cells were treated for either 12 h or 24 h with increasing doses (75 lM, 150 lM and 300 lM) of PAOX inhibitor (MDL72,527, Sigma-Aldrich). Apoptosis was evaluated by Annexin V assay (Annexin V-FITC Kit, Trevigen Inc.) following manufacturer protocol. Briefly, 5 3 10 5 cells were washed with cold PBS and incubated in 100 lL Annexin V Incubation Reagent for 15 min at room temperature in the dark. After staining, cells were analyzed by using a BD FACSCanto II (BD Biosciences; San Jose, CA). At least 10,000 events were counted for each sample to ensure statistical relevance. Early apoptotic cells are Annexin V bright and Propidium Iodide (PI) low, late apoptotic cells or necrotic cells are Annexin V and PI bright, necrotic cells are PI bright only. 20, 21 Methylcellulose and collagen clonogenic assays
The methylcellulose assay was carried out by plating CD341 cells in MethoCultTM GF H4434 (StemCell Technologies Inc.; Vancouver), as previously described. 22 MK colony forming units (CFU-MK) were assayed in collagen-based medium, using a commercial MK assay detection kit (MegaCult-C; StemCell Technologies Inc.) as previously reported. 16 CFU-MKs were scored according to the manufacturer's protocol as small (3-21 cells, deriving from more mature megakaryocyte progenitors), medium (21-49 cells) and large (>50 cells, arising from more primitive MK progenitors) colonies based on their size, which reflects the maturation stage of the progenitor giving rise to each colony.
Morphological and immunophenotypic analysis
Differentiation of CD341 cells was monitored by morphological analysis of May-Grunwald-Giemsa (MCG)-stained cytospins and by flow cytometric analysis of differentiaton markers' expression (Glycophorin A [GPA], CD41, CD42b) at Day 9, 12 and 14 after the last nucleofection. Images were captured by using Ax10scopeA1 microscope equipped with AxioCam ERc 5S Digital Camera and Axion software 4.8 (all Carl Zeiss MicroImaging Inc.; Thornwood, NY). The images were then processed with Adobe Photoshop 7.0 software. The following monoclonal antibodies (MoAbs) were used for flow cytometric analysis: FITC-conjugated mouse anti-human CD41 MoAb, PE-conjugated mouse anti-human CD42b MoAb and PE-conjugated mouse anti-human GPA MoAb (all from Dako; Milano, Italia; http://www.dako.com). After staining, cells were analyzed by using a BD FACSCanto II (BD Biosciences; San Jose, CA). At least 10,000 events were counted for each sample to ensure statistical relevance.
Statistical analysis
The statistics used for data analysis were based on two-tailed Student's t-tests for averages comparison in paired samples. Data were analyzed with Microsoft Excel (Microsoft Office, 2008 release) and are reported as mean 6 standard error of the mean (SEM). A p values less than 0.05 was considered significant.
Results
Array based molecular cytogenetics analysis identifies new recurrent CN alterations in PMF patients
Chromosomal alterations were investigated in 31 PMF samples using Cytoscan HD arrays. Specifically, CN status for each probe set was quantified by comparison with HapMap data (http://hapmap.ncbi.nlm.nih.gov/index.html.en) using the ChAS software. These data were used as input to PREDA, an R bioconductor package suitable to detect regional variations in genomic features from high-throughput data. 11 PREDA identifies relevant chromosomal patterns in high-throughput data using a smoothing approach that accounts for distance and density variability of genomics features. CN data were transformed into a score, which quantifies for each SNP in any sample, the amplitude of the CN variation from the diploid status: the result of this type of analysis is a distribution of statistical scores, each associated to a specific genomic region (window), gain and loss regions were identified as q-value less than 0.01. Genome-wide copy number analysis revealed various numbers of genetic lesions. Figure 1A shows a representation of gain and loss regions across autosomes detected in the sample set. The complete list of chromosomal gains and losses is reported in Table S2 , Supporting Information.
The high resolution potential of Cytoscan HD arrays allowed identifying chromosomal aberrations already known to be associated with PMF, such as gains at 1p36 and 17q25, 23 18, 5q-, 11q-, 13q-, 15q-, 24, 25 together with gains and losses affecting small genomic regions previously not described in the context of PMF, such as gains at 2p25, 4p16, 10q26, 22q13 and losses at 3q13, 4q13, 6p22, 12q24, 19p12 and 22q12 (Table S2 , Supporting Information).
Integrated analysis of gene expression and copy number data identifies novel PMF-associated disease genes
To investigate the potential of these gains and losses to alter molecular mechanisms underlying PMF pathogenesis, we applied an integrated analysis of copy number and gene expression profiles. Copy number and transcriptional data were analyzed using PREDA, a bioinformatics procedure that allows the integration of copy number, obtained from SNP mapping arrays, with transcriptional signals from expression arrays. 10, 11 The integration of genomic and transcriptomic data from the same samples resulted in 11 regions with concomitant chromosomal gain (q-value 0.01) and increased mRNA level (in PMF samples as compared with controls; qvalue 0.5) and 27 regions with concomitant copy number loss (q-value 0.01) and transcriptional down-regulation (qvalue 0.5) (Table 1) . Interestingly, the amplified regions comprise genes such as PXDN, protein involved in extracellular matrix remodeling, 26 and PAOX, a polyamine oxidase that plays an important role in the regulation of polyamine intracellular concentration and has the potential to act as a determinant of cellular sensitivity to the antitumor polyamine analogs ( Figs. 2A and 2B ). On the other hand, in the deleted signature (Figs. 2C and 2D), we found several genes coding for zinc finger proteins such as ZNF92, ZNF107 and ZNF430, not previously reported as being affected in the context of PMF. Moreover, HMGXB4 and ZNF431, negative regulators of WNT and Hedgehog (Hh) pathways, respectively, 27, 28 were also found in the deleted signature. Finally, worth of notice is YTHDC1, 29 a splicing factor whose loss has been recently associated with poor overall and disease-specific survival in endometrial cancer. 30 Mutations of the spliceosome machinery have been recently described in MPNs as well as in myelodysplastic syndromes, 31 but the loss of YTHDC1 locus in PMF patients is first reported in this study. mRNA expression levels of genes included in the amplified and deleted genomic regions reported in Figures 2B and 2D were validated by Real-Time PCR. Overall, more than 90% of the mRNAs showed the same expression pattern described by microarray analysis. In particular, eight out of nine transcripts identified as differentially expressed based on array results, were confirmed by Real-Time PCR as significantly modulated in PMF CD341 cells versus normal donors (Figs. 2E and 2F).
PAOX inhibition induces cell death in PMF cells
The integrative analysis evidenced the concordant increase in copy number and gene expression of the polyamine oxidase PAOX in PMF samples. Previous reports showed that PAOX inhibition could lead to apoptosis in IL3-dependent 32D cells, without affecting mouse spleen hematopoietic precursor cells' 
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survival. 32 To assess the impact of PAOX deregulation on the survival of PMF and normal primary hematopoietic cells, PMF and normal donors cells were incubated with increasing doses of the PAOX inhibitor MDL-72,572. MDL-72,572 induced rapid cell death of PMF CD341cells (5. 3EH) . Similar data were obtained on MNCs isolated from PMF patients and normal donors ( Fig. 1, Supporting Information) .
These results suggest that the copy number gain at 10q26, leading to PAOX up-regulation, could promote myeloid cells resistance to apoptosis in the context of PMF.
HMGXB4 silencing favors megakaryocyte differentiation potential of HSPCs
Among the genes comprised in deleted regions, HMGXB4, ZNF431, ZNF92, ZNF107 and YTHDC1 are of particular interest. Previous evidences showed that HMGXB4 mRNA is preferentially expressed during megakaryocyte (Mk) differentiation, 33 whereas ZNF431, ZNF92, ZNF107 and YTHDC1 mRNAs are steadily expressed throughout the hematopoietic development (data not shown). To assess whether the downregulation of these selected genes, observed in PMF samples, could play a role in the development of myeloproliferative diseases, we performed RNAi-mediated gene silencing experiments. CD341 cells were transfected with a mixture of three Silencer Select siRNAs targeting respectively ZNF431, ZNF92, ZNF107 or YTHDC1 mRNAs (Table S3 , Supporting Information) and with a non-targeting siRNA as a negative control (NegCTR). The expression level of target mRNAs in control samples and siRNA-treated cells was assessed by qRT-PCR at 24 h after the last nucleofection. Even though significant down-regulation of target mRNAs was achieved via RNAimediated gene silencing, no evident effect was observed on either CD341 cell proliferation, survival or differentiation toward any of the hematopoietic lineages (data not shown).
On the other hand, flow cytometric analysis of CD41 and CD42b Mk markers performed on serum-free Mk uni-lineage culture at Day 9, 12 and 14 showed that HMGXB4 silencing (Fig. 4D ) induces a significant increase in the Mk fraction compared with the NegCTR sample (Fig. 4) . In particular, flow cytometry data highlighted an increase of the immature megakaryocyte population (CD411 CD42b2 cells) in HMGXB4-siRNA compared with NegCTR cells (Figs. 4A and  4B ). Next, we examined the effect of HMGXB4 silencing on Mk commitment by plating NegCTR and HMGXB4-siRNA CD341 cells in a collagen-based serum-free semisolid culture medium that supports Mk progenitors' growth in vitro. Results evidenced that HMGXB4 silencing induces a remarkable increase in colony-forming unit-megakaryocytes (CFU-Mk) and a strong decrease of non-megakaryocyte colonies (CFU non-Mk) compared with the NegCTR sample (Fig.  4C) . More in detail, the CFU-Mks scoring showed remark-able differences in small CFU-MKs between HMGXB4-siRNA and NegCTR samples, demonstrating that HMGXB4 silencing affects mainly early steps of megakaryocyte differentiation (Fig. 4C) . Consistently with these observations, morphological evaluation of MGG-stained cytospins at Day 12 and 14 after the last nucleofection clearly displayed a considerable enrichment in Mk precursors at different stages of maturation in HMGXB4-siRNA cells compared with NegCTR (Fig. 4E) .
When performed in erythroid uni-lineage culture, HMGXB4 silencing repressed the erythroid differentiation, as indicated by a decrease in the percentage of cells positive for the erythroid marker GPA (10.8% 6 5.6 in HMGXB4-siRNA vs. 24.8% 6 5 in NegCTR, p < 0.05) (Fig. 5A ) and by the reduction of immature erythroblasts, such as proerythroblasts and basophilic erythroblasts, in HMGXB4-siRNA compared with NegCTR, particularly at Day 9 of culture (Fig. 5C ). In agreement with liquid culture data, methylcellulose-based clonogenic assay showed a significant decrease in Burst Forming Unit-Erythroid (BFU-E) and Colony-Forming Unit-Erythroid (CFU-E) in HMGXB4-siRNA compared with NegCTR sample (Fig. 5B) .
Finally, we did not notice significant modulations in granulocytic and mono-macrophage lineage differentiation between HMGXB4-siRNA CD341 cells and the NegCTR sample (data not shown).
Taken together, these data suggest that HMGXB4 silencing in human Hematopoietic Stem/Progenitor Cells (HSPCs) favors megakaryocyte differentiation while restraining the erythroid lineage.
Discussion
In the last decade several genomic abnormalities have been reported in PMF patients depicting a complex genomic landscape. [1] [2] [3] 5, 6 Although most of the genomic abnormalities described to date seems to impact to a certain degree on JAK2 signaling pathway, it is not yet clear whether and how these abnormalities contribute to disease initiation, clonal evolution or blastic transformation. Here we present a combined approach of high-resolution genomic and gene expression profiling aimed at identifying novel oncogenic lesions and dysregulated pathways in PMF patients.
In agreement with previous reports, our study highlighted several recurrent genomic gains and losses, already described by conventional karyotyping or Comparative Genomic Hybridization (CGH) arrays, such as 18, 5q-, 11q-, 13q-or 15q-. 24 Moreover, the high resolution of copy number data allowed the identification of novel gains and losses affecting small genomic regions previously not described in the context of PMF, such as gains at 2p25, 4p16, 10q26, 22q13 and losses at 3q13, 6p22, 12q24, 19p12 and 22q12 (Table S2 , Supporting Information). Worth of notice, gain on 4p16 affects a genomic region previously reported as involved in a reciprocal (4;15) translocation in few cases of Ph-negative MPNs and Chronic Myeloid Leukemia; 34 within this region is located STK32B, a gene encoding for a serin/threonine protein kinase. Gain on 22q13 affects a region involved in the t(1;22) translocation, commonly described in acute megakaryoblastic leukemia, 35 and containing genes as MKL1, PDGFB, TCF20 and FBLN1. PDGFB gene is a member of the platelet-derived growth factor family, TCF20 encodes for a transcription factor that recognizes the platelet-derived growth factor-responsive element, while FBLN1 mediates platelet adhesion via fibrinogen. The 3q13 region has been reported as recurrent Minimal Deleted Region (MDR) in relapsed Acute Myeloid Leukemia (AML) patients. 36 Deletion affecting the short arm of chromosome 6 has been associated with MPN progression to AML. 37, 38 Likewise, loss on 12q24 involves a genomic region frequently affected by deletion in different types of tumors and leukemias. 39 Very recently, aberrations involving chromosome 12 have been described in MPN patients, and in particular 12q24 abnormalities have been associated with poorer outcomes. 40 To deepen the search for genomic lesions that could influence or have a functional impact on the pathological phenotype, we integrated copy number data with gene expression signals. The integrative analysis identified 38 genomic regions (11 amplified and 27 deleted) with concordant alteration in CN and transcriptional levels. Worth to notice, this analysis revealed amplification on chromosome 10 associated with concordant copy number gain and transcriptional up-regulation of PAOX in PMF samples. PAOX is a polyamine oxidase that plays an important role in the regulation of cellular sensitivity to the antitumor polyamine analogs. Inhibition of PAOX effectively induces cell death in PMF CD341 cells and MNCs without affecting normal myeloid cell survival. These results suggest that PAOX might represent a novel interesting therapeutic target for the specific eradication of neoplastic cells, particularly in those patients carrying the amplification on chromosome 10q26.
Among deleted regions, of particular interest were chromosomal losses affecting 19p13.11-19p12 and 22q12. In the first region, the most down-regulated gene in PMF was ZNF431 located at 19p12. ZNF431 is a nuclear transcriptional repressor, directly targeting Patched1 and likely inhibiting hedgehog response. 27 Given several evidence connecting Hh signaling pathway to the development of myeloid malignancies, 41 we investigated the role of ZNF431 in human HSPCs. In particular, we silenced ZNF431 in HSPCs but its downregulation resulted in no significant difference on cell proliferation, survival or differentiation. This result could be due to the high degree of similarity found in ZNF proteins: ZNF431 is located on chromosome 19p12, together with two other ZNF proteins (ZNF430 and ZNF506), with similar functional domains, 42 that could therefore compensate for ZNF431 silencing.
Moreover, among the most frequently altered genomic regions, our integrative analysis pointed out a region on chromosome 22q12, with the most strongly down-regulated gene being HMGXB4. HMGXB4, also known as HMG2L1, is non-histone chromosomal protein, belonging to the family of High Mobility Group (HMG)-box containing proteins. This protein has been shown to negatively regulate WNT/b-catenin signaling pathway in Xenopus. 28 Several reports demonstrated that activation of WNT signaling pathway through nuclear localization of b-catenin is linked to development and progression of AML, 43, 44 Based on these premises, we studied the role played by HMGXB4 in human HSPCs to assess whether the down-regulation observed in PMF samples could indeed be linked to PMF development. Our data demonstrated that HMGXB4 silencing in human HSPCs favors megakaryocyte differentiation while inhibiting erythroid differentiation. Therefore HMGXB4 loss/down-regulation observed in PMF patients could contribute to the abnormal expansion of the Mk lineage, frequently associated with PMF. 13 To our knowledge, this is the first report describing a role for HMGXB4 in the hematopoietic system.
Taken together, these data suggest that the integration of copy number and gene expression profiles is a powerful tool to identify genomic alterations that may have a functional impact on disease pathogenesis. Our integrative analysis identified the amplification and the deletion of genomic regions that might have not been highlighted by individual gene expression or copy number data analysis. Our results pointed out the concordant loss and down-regulation affecting the HMGXB4 locus in PMF patients that could be responsible for the aberrant megakaryopoiesis observed in PMF. Moreover, we described the gain at 10q26 with resulting upregulation of the PAOX mRNA, allowing the identification of a novel therapeutic target for the selective eradication of PMF cells.
In conclusion, our work sheds light on the influence of genomic abnormalities on gene expression regulation in PMF CD341 cells and on their impact to features typical of PMF, such as a hyperplastic megakaryopoiesis and resistance to apoptosis, and therefore potentially contributing to the development of the myeloproliferative disease.
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